Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows Leave a reply LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp acceleration in global wealth migration in 2025 is colliding with rapidly diverging private healthcare costs worldwide, making the availability and costs of reliable private care a decisive factor in where high-net-worth families choose to live, invest, and secure residence or citizenship rights. New client data released today by global leaders in citizenship and residence planning, Henley & Partners, confirms record demand for cross-border planning and highlights healthcare cost exposure as a critical “hidden variable” shaping long-term destination decisions for globally mobile families. Record Global Demand is Reshaping Priorities Henley & Partners has received applications from 92 nationalities this year (2025) and supported demand across 50+ residence and citizenship programs. Over the past five years, the firm has assisted applicants from 136 nationalities, underscoring the scale and diversity of today’s wealth-migration movement. Comparing the first three quarters of 2024 with the same period in 2025, the firm has seen a 43% increase in applications — a clear signal of intensifying cross-border mobility among affluent families. “Global mobility is becoming a core risk-management strategy for wealthy families,” according to Dr. Christian H. Kaelin, Chairman of Henley & Partners. “As clients build lives across multiple jurisdictions, they are scrutinizing not only access to residence and citizenship, but also the real cost of sustaining that lifestyle — especially the price of reliable private healthcare. Destinations that look attractive on paper can become far less so once true healthcare exposure is understood.” New Evidence Turns Healthcare Costs into a Core Mobility Metric To support clients’ destination decisions, Henley & Partners is referencing the newly published SIP Health Cost Index (HCI) 2025 — a systematic benchmark of the true cost of private healthcare for internationally mobile individuals and families

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting Leave a reply DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy. BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) — Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with second-line, relapsed or refractory large B-cell lymphoma (r/r LBCL) who were transplant-ineligible due to age, comorbidities, or other medical reasons. The primary analysis showed that zamto-cel demonstrated significant and clinically meaningful superiority over chemoimmunotherapy (R-GemOx) in transplant-ineligible patients who were at a high risk of rapid disease progression.1 This study population was characterized by older age and clinically high-risk disease features: the median age was 74 years, 57% of patients had a high International Prognostic Index (IPI≥ 3) and 67% presented with stage III/IV disease. Zamto-cel was well tolerated in this predominantly older and high-risk population.1 Dr. Peter Borchmann, Lead investigator of DALY 2-EU trial and Assistant Medical Director in the Department of Hematology and Oncology at the University Hospital of Cologne, Germany, said: “Zamto-cel demonstrated clinically meaningful and statistically significant superiority over R-GemOx in transplant-ineligible patients with high-risk disease, improving event-free survival while maintaining a favorable tolerability profile. These findings highlight the potential of zamto-cel as an important new treatment option for a clinically vulnerable patient population with

Cochin Shipyard to build next-generation electric TRAnsverse tugs for Svitzer Leave a reply Cochin, India and Copenhagen, Denmark – 8 December 2025. Svitzer, a leading global towage provider, and Cochin Shipyard Limited (CSL), India’s largest public sector shipyard, have signed a shipbuilding agreement for four 26-metre electric TRAnsverse (“TRAnsverse 2600e”) tugs to be constructed in India for Svitzer’s global fleet renewal and growth plans.  Svitzer Nobbys TRAnsverse 3200 Pictured: A TRAnsverse 3200 tug. Svitzer’s agreement with Cochin Shipyard covers the related TRAnsverse 2600e electric tugs The agreement confirms a Letter of Intent signed in October 2025 at India Maritime Week and marks the move from intent to a contracted new build agreement. Under the agreement, CSL will build a minimum of four battery-electric TRAnsverse 2600e tugs for Svitzer, with an option for up to four additional vessels. The tugs will be constructed to Svitzer’s specifications at CSL’s facilities in Cochin to serve as global fleet renewal and advancement in operations worldwide. The vessels complement a wider newbuilding program of the TRAnsverse tug design, cementing Svitzer’s confidence in the vessel’s capabilities while also opening opportunities for future deployment in Indian ports and terminals. SVITZER Barrington Svitzer Barrington operating in Australia The deal brings together Svitzer’s global expertise in sustainable towage solutions with CSL’s proven shipbuilding capabilities, skilled workforce and local innovation. It supports India’s ambition to become a global maritime manufacturing and skills hub under Maritime India Vision 2030, Maritime Amrit Kaal Vision 2047 and the “Make in India” initiative. Kasper Karlsen COO Kasper Karlsen, Svitzer’s Chief Operating Officer The TRAnsverse 2600e tugs are the electric version of the next-generation tug design proving itself as the world’s most advanced and efficient tug. The ‘Swiss Army Knife’ of tugs: the TRAnsverse design can operate in complex and close-quarter operating contexts, with all ship types and sizes in challenging weather and